Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 12, 2010, Pages 3027-3036

  Yang, Yu Xiao ^a   Habel, Laurel A ^b   Capra, Angela M ^b   Achacoso, Ninah S ^b   Quesenberry Jr , Charles P ^b   Ferrara, Assiamira ^b   Levin, Theodore R ^b   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIGMOIDOSCOPY;

ADENOMA; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 78650362478     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0486     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-87.
3. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995;6:164-79.
4. Poulsen M, Molck AM, Thorup I, Breinholt V, Meyer O. The influence of simple sugars and starch given during pre- or post-initiation on aberrant crypt foci in rat colon. Cancer Lett 2001;167:135-43.
5. Caderni G, Bianchini F, Mancina A, Spagnesi MT, Dolara P. Effect of dietary carbohydrates on the growth of dysplastic crypt foci in the colon of rats treated with 1,2-dimethylhydrazine. Cancer Res 1991;51:3721-5.
6. Bruce WR, Archer MC, Corpet DE, et al. Diet, aberrant crypt foci and colorectal cancer. Mutat Res 1993;290:111-8.
7. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-54.
8. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 2004;13:915-9.
9. Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 1999;10:379-86.
10. Yamada K, Araki S, Tamura M, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998;27:794-8.
11. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiology Biomarkers Prev 2003;12:412-8.
12. Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:850-5.
13. Lin J, Ridker PM, Pradhan A, et al. Hemoglobin A1c concentrations and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:3010-2.
14. Lewis JD, Capra AM, Achacoso NS, et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology 2008;135:1914-23.
15. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-402.
16. Rinaldi S, Rohrmann S, Jenab M, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008;17:3108-15.
17. Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers?JAMA 2010;303:446-7.
18. Johnson JA, Yasui Y. Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations. Diabetologia 2010;53:1823-6.
19. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044-50.
20. Currie CJ, Poole CD, Gale EA, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
21. Lieberman DA, de Garmo PL, Fleischer DE, Eisen GM, Chan BK, Helfand M. Colonic neoplasia in patients with nonspecific GI symptoms. Gastrointest Endosc 2000;51:647-51.
22. Rex DK. Colonoscopy: a review of its yield for cancers and adenomas by indication. Am J Gastroenterol 1995;90:353-65.
23. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9.